Drugs / Decitabine/Cedazuridine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06327685 | Mar 2024 → Mar 2027 expected | systemic mastocytosis with an associated clonal hematologic non-mast cell lineage disease | H. Lee Moffitt Cancer Center and Research Institute | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Decitabine/Cedazuridine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06327685 ↗ |
| Route | Oral | “Decitabine/Cedazuridine is a combination medicine given orally.” NCT06327685 ↗ |